Market Access Therapeutic or cosmetic? Patent strategies for dual-use inno... In the pharmaceutical and cosmetic sectors, innovation often stems from discovering new applications for known compounds.
Sales & Marketing Regulators vs weight loss ads: Time to rethink the rules? “Medicated weight loss isn’t cheating.” Since I first wrote about the rise of
News Lilly uses Oscars ad to warn about 'untested' GLP-1s Eli Lilly has used an Oscars ad to urge people not to use unapproved and untested weight-loss medicines in a swipe at the compounding sector.
Patients A new GLP-1 opportunity for pharma: Supporting patients’ emo... People with obesity in Western cultures have largely been subject to shame, blame, stigma, and discrimination that condemns them for their current situation while simultaneously scorning th
R&D Weight loss gold rush: Developers vie for next blockbuster t... Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and Novo Nordisk’s therapies.
Market Access Weight loss treatments bring in billions but capacity remain... The high demand for weight loss treatments has made their rollout a staggered process.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.